MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462170 | Name: Remdesivir maleate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. It was developed as a treatment for filovirus infections such as Ebola virus disease and Marburg virus. Remdesivir was approved for treatment of COVID-19.

Chemical Structure

Remdesivir maleate
Remdesivir maleate
CAS#2250110-53-1 (maleate)

Theoretical Analysis

MedKoo Cat#: 462170

Name: Remdesivir maleate

CAS#: 2250110-53-1 (maleate)

Chemical Formula: C31H39N6O12P

Exact Mass: 0.0000

Molecular Weight: 718.66

Elemental Analysis: C, 51.81; H, 5.47; N, 11.69; O, 26.71; P, 4.31

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1809249-37-3 (free base) 2250110-53-1 (maleate)
Synonym
Remdesivir maleate; GS-5734; GS5734; GS 5734;
IUPAC/Chemical Name
(S)-2-Ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate maleate
InChi Key
SHXZEGNLALLKFB-OOHSPWKBSA-N
InChi Code
InChI=1S/C27H35N6O8P.C4H4O4/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22;5-3(6)1-2-4(7)8/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31);1-2H,(H,5,6)(H,7,8)/b;2-1-/t17-,21+,23+,24+,27-,42?;/m0./s1
SMILES Code
C[C@H](NP(OC1=CC=CC=C1)(OC[C@H]2O[C@@](C#N)(C3=CC=C4C(N)=NC=NN43)[C@H](O)[C@@H]2O)=O)C(OCC(CC)CC)=O.O=C(O)/C=C\C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>3 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Upon entry into cells, remdesivir metabolizes into the nucleotide triphosphate GS-441524. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h. Remdesivir inhibits both epidemic and zoonotic coronaviruses.
In vitro activity:
The combination treatment of remdesivir plus chloroquine resulted in an antagonistic interaction in normal human bronchial epithelial cells. The findings of this study indicate that the combined use of interferon-β plus remdesivir induces maximal antiviral activity against human coronavirus strain OC43 in primary human respiratory epithelial cells. Reference: J Interferon Cytokine Res. 2023 Jan;43(1):35-42. https://pubmed.ncbi.nlm.nih.gov/36651846/
In vivo activity:
Remdesivir treatment can restore the levels of miRNAs that are upregulated in COVID-19 patients to the range observed in healthy subjects. Three miRNAs (hsa-miR-7-5p, hsa-miR-10b-5p, and hsa-miR-130b-3p) were found to be upregulated in patients receiving remdesivir treatment and in patients who experienced natural remission. These upregulated miRNAs could serve as biomarkers of COVID-19 remission. Reference: Arch Virol. 2023 Jun 28;168(7):194. https://pubmed.ncbi.nlm.nih.gov/37380930/

Preparing Stock Solutions

The following data is based on the product molecular weight 718.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Hickerson BT, Sheikh F, Donnelly RP, Ilyushina NA. Comparison of the Antiviral Activity of Remdesivir, Chloroquine, and Interferon-β as Single or Dual Agents Against the Human Beta-Coronavirus OC43. J Interferon Cytokine Res. 2023 Jan;43(1):35-42. doi: 10.1089/jir.2022.0210. PMID: 36651846; PMCID: PMC9885548. 2. Lee CM, Kang MA, Bae JS, Park K, Yang YH, Lee J, Jang KY, Park SH. An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257. PMID: 35417658. 3. Fayyad-Kazan M, Makki R, Homsi ME, Samadi A, Chaaban H, Majzoub RE, Hamade E, Fayyad-Kazan H, Badran B. Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients. Arch Virol. 2023 Jun 28;168(7):194. doi: 10.1007/s00705-023-05825-3. PMID: 37380930. 4. Chen Y, Guo Y, Li S, Xu J, Ning W, Zhao C, Wang J, Qu Y, Zhang M, Zhou W, Cui Q, Zhang H. Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress. Biomed Pharmacother. 2023 Jan;157:114037. doi: 10.1016/j.biopha.2022.114037. Epub 2022 Nov 22. PMID: 36427388.
In vitro protocol:
1. Hickerson BT, Sheikh F, Donnelly RP, Ilyushina NA. Comparison of the Antiviral Activity of Remdesivir, Chloroquine, and Interferon-β as Single or Dual Agents Against the Human Beta-Coronavirus OC43. J Interferon Cytokine Res. 2023 Jan;43(1):35-42. doi: 10.1089/jir.2022.0210. PMID: 36651846; PMCID: PMC9885548. 2. Lee CM, Kang MA, Bae JS, Park K, Yang YH, Lee J, Jang KY, Park SH. An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257. PMID: 35417658.
In vivo protocol:
1. Fayyad-Kazan M, Makki R, Homsi ME, Samadi A, Chaaban H, Majzoub RE, Hamade E, Fayyad-Kazan H, Badran B. Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients. Arch Virol. 2023 Jun 28;168(7):194. doi: 10.1007/s00705-023-05825-3. PMID: 37380930. 2. Chen Y, Guo Y, Li S, Xu J, Ning W, Zhao C, Wang J, Qu Y, Zhang M, Zhou W, Cui Q, Zhang H. Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress. Biomed Pharmacother. 2023 Jan;157:114037. doi: 10.1016/j.biopha.2022.114037. Epub 2022 Nov 22. PMID: 36427388.
1: Siegel D, Hui HC, Doerffler E, et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017;60(5):1648‐1661. doi:10.1021/acs.jmedchem.6b01594